CD86 and Parkinson disease: Furthermore, our analysis of CD62L-CD86+ myeloid DC AC in PD risk, as assessed by the IVW method, showed a negative association (OR = 0.93, 95% CI = 0.89–0.97, p = 0.0005, PFDR = 0.152) and WM analyses showed similar result (OR = 0.92, 95% CI = 0.8–0.98, p = 0.006).